AU7133898A - Nanosized aspartyl protease inhibitors - Google Patents

Nanosized aspartyl protease inhibitors

Info

Publication number
AU7133898A
AU7133898A AU71338/98A AU7133898A AU7133898A AU 7133898 A AU7133898 A AU 7133898A AU 71338/98 A AU71338/98 A AU 71338/98A AU 7133898 A AU7133898 A AU 7133898A AU 7133898 A AU7133898 A AU 7133898A
Authority
AU
Australia
Prior art keywords
nanosized
protease inhibitors
aspartyl protease
aspartyl
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU71338/98A
Inventor
Joshua S. Boger
Pravin Ramsewak Chaturvedi
Roger Dennis Tung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US84401597A priority Critical
Priority to US08844015 priority
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to PCT/US1998/007845 priority patent/WO1998047492A1/en
Publication of AU7133898A publication Critical patent/AU7133898A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
AU71338/98A 1997-04-18 1998-04-14 Nanosized aspartyl protease inhibitors Abandoned AU7133898A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US84401597A true 1997-04-18 1997-04-18
US08844015 1997-04-18
PCT/US1998/007845 WO1998047492A1 (en) 1997-04-18 1998-04-14 Nanosized aspartyl protease inhibitors

Publications (1)

Publication Number Publication Date
AU7133898A true AU7133898A (en) 1998-11-13

Family

ID=25291559

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71338/98A Abandoned AU7133898A (en) 1997-04-18 1998-04-14 Nanosized aspartyl protease inhibitors

Country Status (2)

Country Link
AU (1) AU7133898A (en)
WO (1) WO1998047492A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
AU2004249172A1 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
RU2006130958A (en) * 2004-01-29 2008-03-10 Бакстер Интернэшнл Инк. (Us) Nanosuspension antiretroviral agents for enhanced delivery to the central nervous system
KR20070037444A (en) 2004-06-15 2007-04-04 박스터 헬쓰케어 에스.에이. Ex-vivo application of solid microparticulate therapeutic agents
RU2496482C2 (en) 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Compositions and methods for drug delivery
US8846096B2 (en) 2008-12-12 2014-09-30 Creighton University Nanoparticles and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
EP0495187B1 (en) * 1991-01-15 1997-01-22 Hemosphere, Inc. Protein nanomatrixes and method of production
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
CA2207961A1 (en) * 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same

Also Published As

Publication number Publication date
WO1998047492A1 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
AU685190B2 (en) Human kunitz-type protease inhibitors
DE69727586D1 (en) Cysteine protease inhibitoren
AP1717A (en) Sulfonamide inhibitors of aspartyl protease
AU740263C (en) Thiol sulfonamide metalloprotease inhibitors
AU7967494A (en) Hiv protease inhibitors
AU4074197A (en) Substituted cyclic amine metalloprotease inhibitors
AU5665596A (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
PL323710A1 (en) Reversible inhibitors of cysteinic protease
AU698911B2 (en) Thrombin inhibitors
IL143674D0 (en) Metalloproteinase inhibitors, and the methods for making these
AU688952B2 (en) Thrombin inhibitors
HU0004595A3 (en) Acyclic metalloprotease inhibitors
PT789578E (en) Multicatalitic protease inhibitors
AU2312399A (en) An improved aerosol valve
AU4406497A (en) Reflux inhibitors
ZA9504940B (en) Enzyme inhibitors
PL329441A1 (en) Pyrasinone-type thrombin inhibitors
PL331369A1 (en) Thiosulphonic metaloprotease inhibitors
ZA9800376B (en) Sulfamide-metalloprotease inhibitors
AU4289796A (en) Matrix metalloprotease inhibitors
IL128662D0 (en) Heterocyclic metalloprotease inhibitors
ZA9902447B (en) Quinoxalinones as serine protease inhibitors.
AP9701119A0 (en) THF-containing sulfonamide inhibitors of aspartyl protease
AU3079799A (en) Protease inhibitors in absorbent articles
SG55137A1 (en) Saccharin derivative proteolytic enzyme inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase